Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641373 | 0.96 | RARB (0.44) | LTB4R2RARBMCHR1CACNA1BCYP2D6 | |
| SCHEMBL641495 | 0.90 | LTB4R2 (0.46) | LTB4R2RARBMCHR1CACNA1BCYP2D6 | |
| SCHEMBL641454 | 0.90 | MCHR1 (0.48) | RARBMCHR1THRATHRBTP53 | |
| SCHEMBL642625 | 0.88 | RARB (0.47) | LTB4R2RARBMCHR1CACNA1BCYP2D6 | |
| SCHEMBL643774 | 0.85 | MCHR1 (0.48) | RARBMCHR1THRATHRBTP53 | |
| SCHEMBL641453 | 0.84 | RARB (0.44) | RARBMCHR1THRATHRBTP53 | |
| SCHEMBL641374 | 0.82 | RARB (0.41) | LTB4R2RARBMCHR1CACNA1BCYP2D6 | |
| SCHEMBL642399 | 0.79 | RARB (0.47) | RARBMCHR1THRATHRBTP53 | |
| SCHEMBL642507 | 0.78 | NR1H4 (0.58) | RARBTHRBTP53 | |
| SCHEMBL643717 | 0.77 | MCHR1 (0.51) | RARBMCHR1THRATHRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | claimed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | claimed |
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | LTB4R2 1758/4885RARB 4739/4885MCHR1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.